Lithium is a common medication prescribed to patients with psychiatric disorders, namely bipolar disorder, schizophrenia, and depression. It is used as a mood stabilizer and lessens the intensity of manic episodes, with particular benefit in reducing suicidality. While highly effective, the drug requires routine blood monitoring, which can be uncomfortable, expensive, and inconvenient for patients who must travel to clinical labs for frequent blood testing.
Research from the University of California, Irvine’s Institute for Interdisciplinary Salivary Bioscience (IISBR) points to saliva testing as a potential alternative to blood sampling. Compared to blood sampling, noninvasive saliva collection is easier, requires less processing, and can be carried out in any setting.
A recent study published in the international journal Bipolar Disorders showed a high correlation between saliva and serum lithium levels and that the saliva-serum ratio within an individual could robustly predict a patient’s serum lithium level. These findings suggest that saliva could in fact be used for lithium monitoring among patients with mood disorders.
Over the course of 18 months, researchers collected 171 saliva samples from 75 patients with diagnosed various psychiatric disorders, including bipolar disorder, schizophrenia, schizoaffective disorder, major depressive disorder, or generalized anxiety disorder. According to the team, findings from the study will fill critical gaps in the literature on the efficacy of saliva for drug monitoring. While a large body of work dating back 30 years does exist, researchers say that sample sizes were small, techniques were varied, and older methods were used. The team believes that this new study, as well as the ongoing work being conducted at IISBR, will open the door for the development and implementation of novel salivary testing methods to improve treatment options for patients taking lithium medications, as well as the psychiatric patient experience overall.